Echinomycin: The first bifunctional intercalating agent in clinical trials
The DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index.
Abstract
Echinomycin is a quinoxaline antibiotic that was originally isolated from Streptomyces echinatus. Based on its antitumor activity against two i.p. implanted murine tumors, the B16 melanoma, and the P388 leukemia, it was brought into clinical trials by the National Cancer Institute. Recent studies on its cytotoxic action have related its antitumor activity with its ability to bifunctionally intercalate with double stranded DNA. Toxicologic studies were carried out in CDF1 mice and beagle dogs using intravenous injections. For the mice studies the dose ranges were 288-692 mcg/kg (864-2076 mcg/m2) by single bolus, and 112-254 mcg/kg/day (336-762 mcg/m2/day) for five consecutive days. In the dog, dose ranges studied were 8.9-89.4 mcg/kg (178-1788 mcg/m2) by single bolus, and 3.4-33.5 mcg/kg/day (68-670 mcg/m2/day) for five consecutive days. The major toxic effects were found in the gastrointestinal, hepatic, and lymphoreticular systems. These were reversible at all but the highest dose, in dogs that had been treated for five consecutive days. Phase I clinical trials using various intravenous schedules were sponsored by the National Cancer Institute. Nausea, vomiting, reversible liver enzyme abnormalities, and allergic reactions were the most common toxicities encountered. Based on results from these studies, the National Cancer Institute has recently begun phase II trials in a broad range of diseases. These trials will further characterize echinomycin's toxic effects and its anti…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, minimal or no antitumor activity was found in phase II clinical trials.”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [47]
In the citing paper
“NSC-13502 was brought into clinical trials by the NCI 20 years ago based on its antitumor activity against two i.p. implanted murine tumors, the B16 melanoma and the P388 leukemia (47).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [47]
In the citing paper
“NSC-13502, at 1.2 to 1.5 mg/m 2 once weekly for 4 weeks or once every 3 to 4 weeks (47-50), has been extensively tested in phase I-II clinical trials.”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [47]
Citations
Cites
The Molecular Basis of Antibiotic Action
Gale, E. F. (1981) · Medical Entomology and Zoology · Cited by 1,217
Base Specificity in the Interaction of Polynucleotides with Antibiotic Drugs
Ward, D. C., Reich, E., & Goldberg, I. H. (1965) · Science · doi:10.1126/science.149.3689.1259 · Cited by 477
The Molecular Structure of a DNA-Triostin A Complex
Wang, A. H.-J., Ughetto, G., Quigley, G. J., Hakoshima, T., van der Marel, G. A., van Boom, J. H., & Rich, A. (1984) · Science · doi:10.1126/science.6474168 · Cited by 292
Echinomycin: a bifunctional intercalating antibiotic
Waring, M. J., & Wakelin, L. P. G. (1974) · Nature · doi:10.1038/252653a0 · Cited by 282
Echinomycin Binding Sites on DNA
Van Dyke, M. M., & Dervan, P. B. (1984) · Science · doi:10.1126/science.6089341 · Cited by 218 · cited 1×
“reasons for this preference were demonstrated in recent studies by van Dyke and Dervan utilizing a DNA footprinting method using methidiumpropylEDTA-Fe(II) as the DNA cleaving agent (15).”
MethodThe binding of echinomycin to deoxyribonucleic acid
Wakelin, L. P. G., & Waring, M. J. (1976) · Biochemical Journal · doi:10.1042/bj1570721 · Cited by 161
Stoffwechselprodukte von Actinomyceten. 7. Mitteilung. Echinomycin
Corbaz, R., Ettlinger, L., Gäumann, E., Schierlein, W. K., Kradolfer, F., Neipp, L., Prelog, V., Reusser, P., & Zähner, H. (1957) · Helvetica Chimica Acta · doi:10.1002/hlca.19570400124 · Cited by 96
Huang, C.-H., Mirabelli, C. K., Mong, S., & Crooke, S. T. (1983) · PubMed · Cited by 41
Studies on quinoxaline antibiotics. II. Isolation and properties of quinomycins A, B and C.
Yoshida, T., KATAGIRI, K., & YOKOZAWA, S. (1961) · PubMed · Cited by 34
Waring, M. J., & MAKOFF, A. J. (1974) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13977-1 · Cited by 34
Research works printed but not linked: 2
- Bhatia MC, Thyagarojan TR, Srivastova OP, Anand N, Vora VC: Quinoxaline antibiotics from a Streptomyces species. Indian J Chem 1:277–278, 1963
- Katagiri K, Sugiura K: Antitumor action of the quinoxaline antibiotics. Antimicrob Agents Chemother, (1961): pp. 162–168, 1961
Cited by
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
“implanted murine tumors, the B16 melanoma and the P388 leukemia (47).”
BackgroundModulating Hypoxia-Inducible Transcription by Disrupting the HIF-1–DNA Interface
Nickols, N. G., Jacobs, C. S., Farkas, M. E., & Dervan, P. B. (2007) · ACS Chemical Biology · doi:10.1021/cb700110z · Cited by 126
A Forward Chemical Screen Identifies Antibiotic Adjuvants in Escherichia coli
Taylor, P. L., Rossi, L., Pascale, G. D., & Wright, G. D. (2012) · ACS Chemical Biology · doi:10.1021/cb300269g · Cited by 81
Alshaer, W., Zraikat, M. S., Amer, A., Nsairat, H., Lafi, Z., Alqudah, D. A., Qadi, E. A., Alsheleh, T., Odeh, F., Alkaraki, A., et al. (2019) · RSC Advances · doi:10.1039/c9ra05636j · Cited by 73
Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells
Ponnurangam, S., Dandawate, P. R., Dhar, A., Tawfik, O. W., Parab, R., Mishra, P. D., Ranadive, P., Sharma, R. K., Mahajan, G., Umar, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6560 · Cited by 64
“Several studies have shown that it has antitumor activity with the ability to bifunctionally intercalate with double stranded DNA [5].”
BackgroundInfluential
Metadata
- Authors
- Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B.
- Affiliations
- National Cancer Institute (US)
- ORCID
- Leyland-Jones, Brian
- Venue
- Investigational New Drugs
- Published
- 1985-12
- Volume
- 3
- Issue
- 4
- Pages
- 403-410
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2013828999
- Cited by
- 61
- References
- 18
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Biological Evaluation
- Keywords
- echinomycin, quinoxaline antibiotics, anticancer activity, B16 melanoma, P388 leukemia, dose-limiting toxicity, gastrointestinal toxicity, hepatotoxicity, intravenous administration, anticancer agents
- MeSH terms
- Animals, Clinical Trials as Topic, Cross-Linking Reagents, DNA, Dogs, Drug Evaluation, Echinomycin, Humans, Lethal Dose 50, Neoplasms, Experimental, Quinoxalines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Echinomycin: The first bifunctional intercalating agent in clinical trials. https://app.cochat.ai/papers/10.1007/bf00170766
- The paper
- Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985). Echinomycin: The first bifunctional intercalating agent in clinical trials. Investigational New Drugs. https://doi.org/10.1007/bf00170766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.